In prostate cancer, increased CXCL13 expression has been linked to the regulation of infiltration and proliferation through several signaling pathways, including AKT1/2‐cyclin‐dependent kinases 1/2 (CDK1/2)‐CDK inhibitor 1B (CDKN1B), integrin β3‐focal adhesion kinase (FAK)/Src‐paxillin (PXN), AKT‐JUN‐cyclic AMP response‐element binding protein (CREB1), c‐Jun N‐terminal kinase (JNK), and ERK [17, 18]. Here, SRC is linked to prostate cancer.